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Towards real-time monitoring of artemisinin resistance
The discovery that mutations in the kelch propeller 
domain of the K13 gene (PF3D7_1343700) were major 
determinants of Plasmodium falciparum artemisinin 
resistance has been validated by several studies in the 
Mekong region.1–3 The particularity of this discovery is 
that it took place less than 10 years after the detection 
of the ﬁ rst clinical cases of artemisinin resistance in 
western Cambodia and probably before the spread 
of the mutations to neighbouring malaria-endemic 
regions and beyond.4 This context is very unique and 
favours real-time monitoring of artemisinin resistance 
in endemic areas and anticipation of the risks associated 
with the emergence and spread of the artemisinin-
resistant parasites, a major public health issue. Indeed, 
this situation is completely diﬀ erent to that which 
took place in the late 1970s, when resistant parasites 
emerged to the previous generation of antimalarial 
drugs (ie, chloroquine, sulfadoxine, and pyrimethamine) 
and whose associated molecular markers (eg, Pfcrt, 
Pfdhfr, and Pfdhps) were discovered only after their 
spread to Africa, leading to an un precedented increase 
in morbidity and mortality.5–7 This favourable situation 
should now be used to track the spread of artemisinin 
resistance and mitigate its eﬀ ect on malaria treatment 
and control programmes, especially in sub-Saharan 
Africa.
In The Lancet Infectious Diseases, Kyaw Tun and 
colleagues8 present a detailed molecular study of 
K13 from P falciparum ﬁ eld isolates obtained from 
symptomatic patients at more than 50 diﬀ erent sites in 
Myanmar during 2013–14. The work presented here is 
important and very relevant, because foremost it helps 
identify the extent of resistance in this key country in the 
regional surveillance system. Indeed, the malaria burden 
in Myanmar is the largest in southeast Asia (1·4 million 
malaria cases and 2900 deaths in 2012) and, because 
of its localisation close to the historical epicentre of the 
emergence of multidrug-resistant parasites, this country 
is considered the main route by which drug-resistant 
falciparum malaria will spread contiguously from 
southeast Asia to the Indian subcontinent and then to 
Africa.9 Second, from a methodological point of view, 
Tun and colleagues’ study is a model of what needs to 
be done: a countrywide collection of samples associated 
with a predictive, ﬁ ne-scale (5 × 5 km) geospatial 
representation of the prevalence of K13 mutants. 
Such mapping provides a powerful instrument with 
which to predict the prevalence of K13 mutant alleles 
(or other data) in unsampled areas. The mapping also 
enables national programmes to obtain clear and 
useful information about the extent of resistance and 
thus implement appropriate actions. For the present 
study, the molecular data provide strong evidence that 
artemisinin-resistant falciparum malaria in Myanmar 
extends across much of Upper Myanmar, including 
areas close to the Indian border in the northwest. These 
data, associated with information about the presence 
of K13 mutant alleles in Bangladesh, advocate for a 
rigorous molecular survey to be implemented without 
delay in the Indian subcontinent.10 One of the major 
technical issues raised in the study is the low extraction–
sequencing success rate for samples obtained with 
rapid diagnostic tests (26%). Although this approach 
should be promoted because it allows the collection 
of blood samples of all malaria cases recorded at least 
in the health system, the low extraction–sequencing 
success rate shows that a major eﬀ ort should be made 
to improve the performance of the DNA extraction or 
the PCR ampliﬁ cation, or to modify the format of rapid 
diagnostic tests for use not only as point-of-care testing 
for malaria, but also as blood sample sources.
In the past few decades, substantial developments 
have been made in plasmodium molecular biology and 
they have greatly increased understanding of malaria 
epidemiology. Previously, only incidence and prevalence 
were used to assess the eﬀ ect of malaria control 
measures, but nowadays, with the introduction of high-
sensitivity molecular assays, researchers can investigate 
the origin and the ﬂ ow of malaria-resistant parasites.11 
In all endemic areas, a falciparum gene-ﬂ ow map 
should be envisaged to help implementation of control 
measures and identify key sites for malaria monitoring. 
Importantly, in endemic countries where artemisinin 
resistance has been recorded, a greater parasite biomass 
will be exposed to partner drugs and thus molecular 
surveys must include partner drug monitoring, with use 
of molecular markers if available.2,12
Real-time detection and monitoring of the geospatial 
distribution of antimalarial drug-resistant parasites is 
now a possibility, as is prevention of their dissemination 
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in neighbouring endemic areas. However, substantial 
work remains to be done to harmonise and validate 
collected data. Currently, a major concern is the 
interpretation of molecular data because of the high 
diversity of the K13 gene: except for four mutations 
(C580Y, R539T, R543I, and Y493H), no clinical or in-vitro 
data have been associated with the other K13 mutant 
alleles.1,3 We believe that the scientiﬁ c community 
working on artemisinin resistance should now create 
a consortium around a K13 reference centre that could 
take over the management and data validation, the 
harmonisation of molecular biology techniques, the 
provision of control samples, and the organisation of 
a quality assurance system, to recommend the best 
therapeutic options—a prerequisite to move eﬀ ectively 
toward malaria elimination.
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Rotavirus vaccines roll-out in resource-deprived regions
Rotaviruses cause 30–50% of severe diarrhoea cases 
in children younger than 5 years, leading to about 
450 000 deaths every year.1 Infections during the ﬁ rst 
months of life are protective against symptomatic 
reinfections later on, setting the stage for vaccine 
development.2,3 The existence of four major genotypes—
G1[P8], G2[P4], G3[P8], and G4[P8]—created a great 
challenge because in-vitro studies suggested that 
antibodies to a speciﬁ c type neutralised only that type, 
raising the question of whether it would be necessary 
for a vaccine to include all common genotypes. 
During the 1990s the ﬁ rst licensed vaccine, Rotashield 
(Wyeth Laboratories, Collegeville, PA, USA), which 
contained an attenuated simian and three simian–
human reassortant strains of the virus, showed that 
70–90% of cases of severe rotavirus disease could 
potentially be prevented in lower-middle-income and 
high-income countries with vaccination.4 However, 
intestinal intussusception was induced in about one 
in 11 000 children who received the vaccine, leading 
to its withdrawal and posing a large challenge for new 
candidate vaccines because future trials needed to 
include 60 000 children to reasonably assure safety.5,6 
Post-licensure studies of the second-generation 
vaccines Rotarix (GlaxoSmithKline, Brentford, UK), 
which contains a single human attenuated strain, 
and RotaTeq (Merck, Kenilworth, NJ, USA) based on 
ﬁ ve human-bovine reassortant strains, suggest an 
acceptable class eﬀ ect risk for intestinal intussusception 
of somewhere between one in 20 000 and one in 
100 000 individuals.7 Importantly, both vaccines 
showed high eﬃ  cacy (more than 80%) against severe 
rotavirus disease in prelicensure studies5,6 and against 
several predominating genotypes. As trials were 
progressively done in various regions worldwide, it 
became clear that protective eﬃ  cacy for both vaccines 
was lower in resource-deprived countries than in high-
income countries8 and that eﬃ  cacy might not be the 
same among serotypes and genotypes, especially 
against G2[P4].5,9
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